EUSA, GSK ink $44M pre-clinical antibody deal

EUSA Pharma will keep about half of the $44 million in up front fees and milestones it is scheduled to receive from GlaxoSmithKline for a license covering a pre-clinical antibody targeted at lymphoma and rheumatoid arthritis. The other half goes to its development partner, Vaccines Inc. The antibody--OP-R003--is a protein that targets interleukin-6, a common target for a number of drug developers.

"The out-licensing of this early-stage antibody is another strategic milestone for EUSA, as we continue to focus our business on marketed and late-stage products in the oncology, pain control and critical care areas," said Bryan Morton, CEO of EUSA, a developer based in the U.S. and the U.K.

- read the release for more info

Suggested Articles

Across its 15-year history, Omega Funds has a hand in a clutch of high-profile biotechs such as Editas Medicine and Juno Therapeutics.

After Novartis’ near $10 billion buyout of The Medicines Company, many thought cardiovascular therapies were hot again.

Mutations in RIPK1 can cause uncontrolled cell death and inflammation, researchers discovered by studying families with an autoimmune disorder.